Short-term efficacy and safety of radiofrequency ablation for idiopathic premature ventricular contractions


UÇAR M., ÇETİN N., ÖZYURTLU F., SOYLU M. Ö., ŞAŞMAZ M. İ.

Medicine (United States), cilt.105, sa.8, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 105 Sayı: 8
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1097/md.0000000000047727
  • Dergi Adı: Medicine (United States)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE, Directory of Open Access Journals
  • Anahtar Kelimeler: catheter ablation, electrophysiology, premature ventricular contractions, PVC-induced cardiomyopathy, radiofrequency ablation
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

Premature ventricular contractions (PVCs) are common arrhythmias that may impair quality of life and lead to PVC-induced cardiomyopathy. Radiofrequency ablation (RFA) has emerged as an effective treatment option for symptomatic and drug-refractory idiopathic PVCs, yet real-world data remain limited. This retrospective single-center study included 53 patients who underwent RFA for idiopathic PVCs between December 2022 and June 2024. Demographic, clinical, and procedural data were analyzed. Acute procedural success, 6-month recurrence, and complications were evaluated according to PVC localization. The mean age of the cohort was 52.1 ± 12.9 years, and 62.3% were female. Acute procedural success was achieved in 84.9% of patients. The most frequent origin was the right ventricular outflow tract (60.4%), followed by the left ventricle (26.4%), coronary cusp (11.3%), and para-Hisian region (1.9%). At 6-month follow-up, recurrence occurred in 6.6% of patients. Complications included 2 cases of steam pop with mild pericardial effusion and 2 cerebrovascular events, both with complete recovery. Age was identified as an independent predictor of acute procedural success (P < .05). RFA is a safe and effective treatment for idiopathic PVCs, providing high acute success and low recurrence rates. Early intervention in symptomatic or drug-refractory patients may improve outcomes and help prevent PVC-induced cardiomyopathy.